Filing Flows › Mereo BioPharma Group (MREO) › Who owns the stock
Who owns Mereo BioPharma Group (MREO) stock
56 funds reported Mereo BioPharma Group (MREO) shares in their latest 13F filings, worth $18.0M in all. The largest holder is Rubric Capital Management LP ($4.9M). Last quarter 22 funds added to their stakes and 26 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Rubric Capital Management LP | 15,307,347 | $4.9M | unchanged | 2026-06-30 |
| 683 Capital Management, LLC | 11,777,856 | $3.7M | decrease | 2026-06-30 |
| Bank of America | 8,195,281 | $2.6M | decrease | 2026-06-30 |
| Defilade Capital Management, L.P. | 7,558,756 | $2.4M | unchanged | 2026-06-30 |
| Newtyn Management, LLC | 3,000,000 | $953K | decrease | 2026-06-30 |
| Tejara Capital | 2,037,520 | $647K | unchanged | 2026-06-30 |
| UBS Group AG | 1,447,627 | $460K | decrease | 2026-06-30 |
| Two Sigma Investments, LP | 1,319,241 | $419K | increase | 2026-06-30 |
| EcoR1 Capital, LLC | 1,000,000 | $318K | decrease | 2026-06-30 |
| Jane Street Group, LLC | 774,944 | $246K | increase | 2026-06-30 |
| Ishara Investments LP | 768,750 | $244K | new | 2026-06-30 |
| Wealthspire Advisors, LLC | 765,000 | $243K | decrease | 2026-06-30 |
| Citadel Advisors LLC | 444,158 | $141K | new | 2026-06-30 |
| Rangeley Capital, LLC | 329,200 | $105K | unchanged | 2026-06-30 |
| Susquehanna International Group, LLP | 213,270 | $68K | increase | 2026-06-30 |
Mereo BioPharma Group's latest quarter
Mereo BioPharma Group, Q2 2025: revenue $500K, net loss $14.6M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most MREO stock?
By the latest 13F filings: Rubric Capital Management LP ($4.9M); 683 Capital Management, LLC ($3.7M); Bank of America ($2.6M); Defilade Capital Management, L.P. ($2.4M); Newtyn Management, LLC ($953K).
What is the short interest in MREO?
3,229,718 shares were sold short at the 2026-10-15 settlement, 20.58% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.